drugset / Trial / NCT01832896
Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to evaluate the safety and tolerability of a single Subcutaneous (SC) dose of Ecallantide in children and adolescents with Hereditary Angioedema (HAE).
Timeline
- Start
- 2013-08
- Primary completion
- 2017-07
- Completion
- 2017-12
Outcome
Outcome not reported
Stopped: “PI indicated departure from institution, inability to complete study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ecallantide | Protein / enzyme biologic | 10 mg | Subcutaneous |
| Subject | ecallantide | Protein / enzyme biologic | 20 mg | Subcutaneous |
| Subject | ecallantide | Protein / enzyme biologic | 30 mg | Subcutaneous |